 |
|
|
 |
|
FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 The FDA says it is "currently reviewing many sources of safety data for Lantus," including completed and ongoing observational and clinical trials, and may ask Sanofi to conduct further trials should they be deemed necessary.
According to the Wall Street Journal, a spokesman for Sanofi said that the company is working with the FDA on this issue and continues to stand behind the drug's safety.
In the meantime, the FDA says it "encourages both health care professionals and patients to report side effects from the use of insulin glargine to the FDA's MedWatch Adverse Event Reporting Program."
Text Continues Below

More information
Find out more about diabetes at the American Diabetes Association.
Page: << Prev | 1 | 2
-- E.J. Mundell
|
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 7/1/2009
|
 |

SOURCES: July 1, 2009, statement, U.S. Food and Drug Administration; June 26, 2009, statement, American Diabetes Association; Wall Street Journal
|